Market research
APTX Aptinyx Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- 0.0%
- Beta
- 1.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03836N1037
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.5
- Dividend yield
- 0.0%
- Beta
- 1.22
About
About Aptinyx Inc
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APTX discussion.
5 years, 4 months ago
Aptinyx Inc is currently in a long term downtrend where the price is trading 15.5% below its 200 day moving average.
From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 100.6.
Aptinyx Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 16.6% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.0% to $-8M since the same quarter in the previous year.
Based on the above factors, Aptinyx Inc gets an overall score of 3/5.